KORU Medical (KRMD) — customer relationships that shape revenue upside and concentration risk

Repro Med Systems, doing business as KORU Medical, designs and sells the Freedom infusion platform and related disposables, monetizing through device sales and recurring consumables sold largely through a small set of distributors and direct pharma customers. Revenue growth is driven by adoption of Freedom for novel biologics and by distributor-led scale in the U.S. and Canada, while margins and cash generation remain constrained by a concentrated go-to-market and an ongoing pivot into novel therapy use cases.

Learn more about how this customer intelligence is assembled at https://nullexposure.com/.

How KORU markets value: a focused device + channel model

KORU’s commercial model is straightforward: sell the Freedom infusion system and consumables to pharmaceutical companies, specialty pharmacies and home-infusion providers, primarily through a handful of distributors. The model creates recurring revenue through disposables and generates outsized sensitivity to a few large customers and regulatory approvals for new drug-device combinations. KORU reported roughly $33.6M in net revenues for 2024 with the domestic market accounting for the majority of sales, and continues to pursue label expansions that position Freedom as the delivery platform for specialty biologics.

Operational characteristics that investors should treat as structural signals:

• Concentrated channel posture. The company sells the majority of product through three U.S. and three international distributors; those six partners accounted for ~75% of revenues as of Dec‑31, 2024. This creates high counterparty concentration and single-distributor dependency risk.
• Geography-weighted exposure. Domestic core (U.S. and Canada) is the dominant revenue pool: management disclosed domestic revenues well above international receipts for 2024. Growth or reimbursement shifts in North America will disproportionately affect results.
• Criticality of relationships. Because three distributors generate the majority of product revenue, these relationships are commercially critical rather than peripheral; loss or renegotiation of terms would produce an immediate financial impact.
• Maturity and pathway to scale. The company is on a clear path to scale via novel therapy label expansions (device clearances tied to specific drugs), but profitability remains below breakeven (negative EBITDA and diluted EPS).

If you want a clean view of customer concentration and relationship context, visit https://nullexposure.com/ for the underlying signals.

Customer relationships in the public record

Below are the customer ties surfaced in the public filings and media coverage. Each relationship is summarized in plain language with the originating source noted.

Forecast Ortho — clinical collaboration for joint-replacement complications

KORU announced a collaboration supporting Forecast Ortho’s clinical trials for treatments addressing complications from joint replacement surgeries, positioning Freedom for use in clinical settings tied to orthopedic biologics or local therapies. This was disclosed during KORU’s Q3 2025 earnings call; the exchange was captured in the earnings call transcript in March 2026. (Source: Q3 2025 earnings call transcript, referenced in Q1–Q2 2026 reporting.)

Why it matters: This is a development-stage collaboration that demonstrates KORU’s strategy to embed Freedom in clinical trials and new therapy pathways, which can convert to recurring consumable revenue if trials progress to commercialization. (Source: Q3 2025 earnings call, March 2026.)

UCB — FDA 510(k) clearance for RYSTIGGO delivery on FreedomEDGE

KORU received FDA 510(k) clearance to use the FreedomEDGE infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy commercialized by UCB, broadening the Freedom label to include a global biologic. A Biospace press release covering the clearance was published in March 2026 and describes the regulatory milestone and the branded drug-device linkage. (Source: Biospace press release, March 2026.)

Why it matters: Label expansions tied to recognized pharma brands like UCB accelerate commercial adoption and create higher-margin recurring revenue streams from consumables and device placements; FDA clearance materially increases the addressable market for Freedom in specialty biologics. (Source: Biospace, March 2026.)

What these relationships collectively reveal

These customer signals confirm two strategic threads: first, KORU is actively pursuing label expansions that attach Freedom to specific biologics, and second, commercial scale is delivered primarily through a tight set of distributors rather than a broad direct salesforce. Together these characteristics produce concentrated but potentially high-value revenue streams: regulatory clearances and pharma collaborations can unlock large, recurring revenue contracts, but that upside is counterbalanced by the company's concentrated counterparty exposure and North American revenue bias.

Key takeaways for valuation and risk assessment:

• Concentration is the dominant risk factor. Six distributors accounted for ~75% of net revenues (Dec‑31, 2024), and one U.S. distributor contributed approximately 35%; investors should model scenarios where distributor terms change or a large partner reduces purchases.
• Regulatory approvals drive optionality. Each label expansion—such as the UCB RYSTIGGO clearance—translates directly into a larger addressable market for consumables and device placements. Treat approvals as binary catalysts for demand acceleration.
• Geographic skew amplifies macro sensitivity. Domestic core (U.S. + Canada) accounts for the bulk of revenues; international growth exists but is a smaller base. Exchange-rate or reimbursement shifts in North America have outsized impact.

For a concise dossier on customer concentration and distribution risk, see https://nullexposure.com/.

How investors and operators should act

Investors should price KORU with a dual lens: reward for regulatory-driven top-line optionality, and discount for counterparty concentration and negative operating leverage. Monitor three items closely:

1. Renewals or term changes with the top distributors and disclosure of distributor-level revenue splits.
2. Commercial rollout metrics tied to new labels (units placed, consumables per patient, adoption velocity) from partners like UCB.
3. International channel expansion that reduces North American concentration.

Operators should prioritize diversification of distribution partners, deepen direct relationships with large pharma customers, and convert label wins into repeatable consumable purchase patterns to improve margin stability.

Bottom line

KORU Medical’s near-term value is shaped by a small number of highly critical distributor relationships and by label expansions with pharma partners that convert regulatory wins into repeatable revenue. Investors should balance the upside in biologic-driven adoption—illustrated by the UCB clearance—against the concentration and geography risks embedded in the current go-to-market model.

Explore more customer-driven signals and relationship analytics at https://nullexposure.com/ — the fastest way to add customer intelligence into investment or operational due diligence.